{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:52:22Z","timestamp":1792043542977,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-025-24878-4","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:53:23Z","timestamp":1761047603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost effectiveness of female HPV vaccines for routine childhood immunisation schedule in T\u00fcrkiye"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5854-6549","authenticated-orcid":false,"given":"\u00c7a\u011fr\u0131 Emin","family":"\u015eahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2964-3056","authenticated-orcid":false,"given":"Selma","family":"Karabey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"24878_CR1","doi-asserted-by":"crossref","unstructured":"Plotkin S. History of vaccine Development. 4 ed. New York: Springer; 2011.","DOI":"10.1007\/978-1-4419-1339-5"},{"key":"24878_CR2","doi-asserted-by":"crossref","unstructured":"Jamison D, Breman J, Measham A, Alleyne G, Claeson M, Evans D ve ark. Disease control priorities in developing countries. 2nd edition. Washington DC: The World Bank Group Archived January 23, 2013;\u00a02006.","DOI":"10.1596\/978-0-8213-6179-5"},{"issue":"1\u20132","key":"24878_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.virol.2013.04.023","volume":"445","author":"EM de Villiers","year":"2013","unstructured":"de Villiers EM. Cross-roads in the classification of papillomaviruses. Virology. 2013;445(1\u20132):2\u201310.\u00a0https:\/\/doi.org\/10.1016\/j.virol.2013.04.023","journal-title":"Virology"},{"issue":"suppl 1","key":"24878_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/rmv.1822","volume":"25","author":"J Doorbar","year":"2015","unstructured":"Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(suppl 1):2\u201323.","journal-title":"Rev Med Virol"},{"key":"24878_CR5","doi-asserted-by":"crossref","unstructured":"Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez B, Xiao W, Kim E ve ark. Human papillomavirus and rising oropharyngeal cancer incidence in the united States. J Clin Oncol. 2011;29(32):4294\u2013301.","DOI":"10.1200\/JCO.2011.36.4596"},{"issue":"10 Suppl","key":"24878_CR6","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1002\/cncr.23764","volume":"113","author":"ML Gillison","year":"2008","unstructured":"Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113(10 Suppl):3036\u201346.","journal-title":"Cancer"},{"issue":"32","key":"24878_CR7","doi-asserted-by":"publisher","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","volume":"68","author":"E Meites","year":"2019","unstructured":"Meites E, Szilagyi PG, Chesson HW, Unger E, Romero J, Markowitz L. Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices. MMWR Morbidity Mortal Wkly Rep. 2019;68(32):698\u2013702.","journal-title":"MMWR Morbidity Mortal Wkly Rep"},{"key":"24878_CR8","unstructured":"Strategic Advisory Group of Experts (SAGE) on Immunization. Working Group onpotential contribution of Human Papillomavirus (HPV) vaccines and immunization towards cervical cancer elimination Background Report. 2019."},{"key":"24878_CR9","unstructured":"World Health Organization. Global market study: HPV vaccines. Geneva: World Health Organization; 2019."},{"issue":"19","key":"24878_CR10","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1016\/j.vaccine.2018.03.060","volume":"36","author":"SS Ng","year":"2018","unstructured":"Ng SS, Hutubessy R, Chaiyakunapruk N. Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-valent vaccine compared to bivalent and quadrivalent vaccines. Vaccine. 2018;36(19):2529\u201344. https:\/\/doi.org\/10.1016\/j.vaccine.2018.03.060.","journal-title":"Vaccine"},{"issue":"22","key":"24878_CR11","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1016\/j.vaccine.2017.03.096","volume":"35","author":"M D\u2019Addario","year":"2017","unstructured":"D\u2019Addario M, Redmond S, Scott P, Egli-Gany D, Riveros-Balta AX, Henao Restrepo AM, Low N. Two-dose schedules for human papillomavirus vaccine: systematic review and meta-analysis. Vaccine. 2017;35(22):2892\u2013901. https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.096.","journal-title":"Vaccine"},{"key":"24878_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10198-018-0996-9","volume":"20","author":"V Qendri","year":"2019","unstructured":"Qendri V, Bogaards JA, Berkhof J. Pricing of HPV vaccines in European tender-based settings. Eur J Health Econ. 2019;20:271\u201380. https:\/\/doi.org\/10.1007\/s10198-018-0996-9.","journal-title":"Eur J Health Econ"},{"key":"24878_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40258-018-0375-9","volume":"16","author":"L Garattini","year":"2018","unstructured":"Garattini L, Padula A. Pricing of HPV vaccines in europe: back to the future? Appl Health Econ Health Policy. 2018;16:275\u20137. https:\/\/doi.org\/10.1007\/s40258-018-0375-9. http:\/\/sci-hub.tw\/.","journal-title":"Appl Health Econ Health Policy"},{"key":"24878_CR14","unstructured":"T.C. Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131. Ulusal Kanser Kontrol Plan\u0131 2013\u20132018. Ankara: Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 Yay\u0131nlar\u0131; 2013. Eri\u015fim adresi: https:\/\/www.iccp-portal.org\/sites\/default\/files\/plans\/Ulusal_Kanser_Kontrol_Plani_2013_2018.pdf"},{"issue":"2","key":"24878_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4274\/tmsj.galenos.2022.09.02.01","volume":"9","author":"J \u00d6zdemir","year":"2022","unstructured":"\u00d6zdemir J, Ayd\u0131n S, Y\u0131lmaz E, et al. HPV, HPV vaccination worldwide, and current status of HPV vaccination in turkey: A literature review. Turk Med Stud J. 2022;9(2):48\u201354. https:\/\/doi.org\/10.4274\/tmsj.galenos.2022.09.02.01.","journal-title":"Turk Med Stud J"},{"key":"24878_CR16","doi-asserted-by":"publisher","unstructured":"Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health. 2014;2(7):e406\u201314. https:\/\/doi.org\/10.1016\/S2214-109X(14)70237-2.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/25103394\/","DOI":"10.1016\/S2214-109X(14)70237-2"},{"key":"24878_CR17","volume-title":"Pricing of HPV vaccines in europe: back to the future?","author":"L Garattini","year":"2018","unstructured":"Garattini L, Padula A. Pricing of HPV vaccines in europe: back to the future? Italy: Appl Health Econ Health Policy; 2018."},{"key":"24878_CR18","volume-title":"Making choices in health: WHO guide to cost-effectiveness analysis","author":"World Health Organization","year":"2003","unstructured":"World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003."},{"key":"24878_CR19","volume-title":"Guide to introducing HPV vaccine into National immunization programmes","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. Guide to introducing HPV vaccine into National immunization programmes. Geneva: World Health Organization; 2013."},{"key":"24878_CR20","doi-asserted-by":"publisher","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","DOI":"10.3322\/caac.21492"},{"issue":"11","key":"24878_CR21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2471\/BLT.11.089862","volume":"89","author":"DS LaMontagne","year":"2011","unstructured":"LaMontagne DS, Barge S, Le NT. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ. 2011;89(11):821\u2013B830. https:\/\/doi.org\/10.2471\/BLT.11.089862.","journal-title":"Bull World Health Organ"},{"key":"24878_CR22","unstructured":"T.C. Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131. Sa\u011fl\u0131k \u0130statistikleri Y\u0131ll\u0131\u011f\u0131 2018 [Health Statistics Yearbook 2018]. Ankara: Sa\u011fl\u0131k Bilgi Sistemleri Genel M\u00fcd\u00fcrl\u00fc\u011f\u00fc; 2019. https:\/\/sbsgm.saglik.gov.tr\/TR-62398\/saglik-istatistikleri-yilligi-2018-yayinlandi.html"},{"key":"24878_CR23","doi-asserted-by":"crossref","unstructured":"Global Health Metrics. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204\u201322.","DOI":"10.1016\/S0140-6736(20)30925-9"},{"key":"24878_CR24","unstructured":"World Health Organization. Guide to introducing HPV vaccine into national immunization programmes. Geneva: World Health Organization; 2016 (reprinted\/updated). https:\/\/www.who.int\/publications\/i\/item\/9789241549769"},{"issue":"6","key":"24878_CR25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/PGP.0b013e3181aaba0d","volume":"28","author":"A Usub\u00fct\u00fcn","year":"2009","unstructured":"Usub\u00fct\u00fcn A, Alemany L, K\u00fc\u00e7\u00fckali T, et al. Human papillomavirus types in invasive cervical cancer specimens from Turkey. Int J Gynecol Pathol. 2009;28(6):541\u20138. https:\/\/doi.org\/10.1097\/PGP.0b013e3181aaba0d.","journal-title":"Int J Gynecol Pathol"},{"issue":"10197","key":"24878_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","volume":"394","author":"M Drolet","year":"2019","unstructured":"Drolet M, B\u00e9nard \u00c9, P\u00e9rez N, Brisson M, HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497\u2013509. https:\/\/doi.org\/10.1016\/S0140-6736(19)30298-3.","journal-title":"Lancet"},{"key":"24878_CR27","doi-asserted-by":"crossref","unstructured":"Munoz N, Castellsagu\u00e9 X, de Gonz\u00e1lez AB, Gissmann L. HPV in the etiology of human cancer. Vaccine. 2006;24:S1\u2013S10.","DOI":"10.1016\/j.vaccine.2006.05.115"},{"key":"24878_CR28","unstructured":"World Health Organisation. Human papillomavirus vaccines position paper. Geneva World Health Organization (WHO); 2018. https:\/\/www.who.int\/publications\/i\/item\/who-wer9219-241-268?utm"},{"key":"24878_CR29","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.2147\/IDR.S178381","volume":"12","author":"ZQ Toh","year":"2019","unstructured":"Toh ZQ, Kosasih J, Russell FM, Garland SM, Mulholland EK, Licciardi PV. Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus. Infect Drug Resist. 2019;12:1951\u201367. https:\/\/doi.org\/10.2147\/IDR.S178381. Published 2019 Jul 4.","journal-title":"Infect Drug Resist"},{"key":"24878_CR30","unstructured":"CDC Vaccine Price List. 2018. Son Eri\u015fim Tarihi: 10.10.2020. https:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/2018\/2018-06-01.html"},{"issue":"\u2013","key":"24878_CR31","doi-asserted-by":"publisher","first-page":"e0260808","DOI":"10.1371\/journal.pone.0260808","volume":"16","author":"KL Rosettie","year":"2021","unstructured":"Rosettie KL, et al. Cost-effectiveness of HPV vaccination in 195 countries: global meta-regression analysis. PLoS ONE. 2021;16(\u2013):e0260808. https:\/\/doi.org\/10.1371\/journal.pone.0260808.","journal-title":"PLoS ONE"},{"key":"24878_CR32","unstructured":"PAHO Vaccine Price List. 2018. Son Eri\u015fim Tarihi: 10.10.2020. https:\/\/www.paho.org\/en\/file\/49423\/download?token=_bRKE1W3"},{"key":"24878_CR33","doi-asserted-by":"publisher","unstructured":"Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Glob Health. 2018;3(6):e000964. https:\/\/doi.org\/10.1136\/bmjgh-2018-000964. Erratum in: BMJ Glob Health. 2019;4(3):e000964corr1. https:\/\/doi.org\/10.1136\/bmjgh-2018-000964. PMID: 30483412; PMCID: PMC6231096.","DOI":"10.1136\/bmjgh-2018-000964"},{"key":"24878_CR34","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ijc.20244","volume":"111","author":"N Mu\u00f1oz","year":"2004","unstructured":"Mu\u00f1oz N, Bosch FX, Castellsagu\u00e9 X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278\u201385. https:\/\/doi.org\/10.1002\/ijc.20244.","journal-title":"Int J Cancer"},{"key":"24878_CR35","doi-asserted-by":"publisher","unstructured":"Jiang Y, Ni W, Wu J. Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis. BMJ Open. 2019;9(11):e031186. https:\/\/doi.org\/10.1136\/bmjopen-2019-031186","DOI":"10.1136\/bmjopen-2019-031186"},{"key":"24878_CR36","unstructured":"S\u00f6zmen K, T\u00f6z\u00fcn M, Baydur H, \u00dcnal B. T\u00fcrki\u0307ye\u2019de Servi\u0307ks Kanseri\u0307 Taramas\u0131n\u0131n Yayg\u0131nla\u015ft\u0131r\u0131lmas\u0131n\u0131n ve \u0130nsan Papi\u0307lloma Vi\u0307r\u00fcs A\u015f\u0131s\u0131\u2019n\u0131n Uygulanmas\u0131n\u0131n Mali\u0307yet Etki\u0307li\u0307li\u0307\u011fi\u0307ni\u0307n De\u011ferlendi\u0307ri\u0307lmesi\u0307 17. Ulusal Halk Sa\u011fl\u0131\u011f\u0131 Kongresi Kitap\u00e7\u0131\u011f\u0131. HASUDER. 2014."},{"key":"24878_CR37","unstructured":"World Health Organisation HPV Factsheet. Son Eri\u015fim Tarihi: 10.10.2020 https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/human-papillomavirus-(hpv)-and-cervical-cancer"},{"key":"24878_CR38","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s12913-017-2297-x","volume":"17","author":"H Van Minh","year":"2017","unstructured":"Van Minh H, My NT, Jit M. Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in vietnam: a PRIME modeling study. BMC Health Serv Res. 2017;17:353. https:\/\/doi.org\/10.1186\/s12913-017-2297-x.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"24878_CR39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.vaccine.2019.10.037","volume":"38","author":"RA Mahumud","year":"2020","unstructured":"Mahumud RA, Gow J, Alam K, et al. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh. Vaccine. 2020;38(2):165\u201372. https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.037.","journal-title":"Vaccine"},{"key":"24878_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnma.2020.03.002","author":"A Buskwofie","year":"2020","unstructured":"Buskwofie A, David-West G, Clare CA. A review of cervical cancer: incidence and disparities. J Natl Med Assoc. 2020. https:\/\/doi.org\/10.1016\/j.jnma.2020.03.002.","journal-title":"J Natl Med Assoc"},{"key":"24878_CR41","doi-asserted-by":"publisher","unstructured":"Buskwofie A, David-West G, Clare CA. A review of cervical cancer: incidence and disparities. Journal of the National Medical Association. 2020;112(2):229\u201332.\u00a0https:\/\/doi.org\/10.1016\/j.jnma.2020.03.002","DOI":"10.1016\/j.jnma.2020.03.002"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-24878-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-24878-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-24878-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:53:31Z","timestamp":1761047611000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-025-24878-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24878"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-24878-4","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"12 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since the study data were collected from publicly available sources and analyzed, there are no participants and consent forms. Not applicable.This study was approved by the Istanbul University Clinical Research Ethics Committee (No:2019\/513) on 12.04.2019.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3561"}}